lifestyle.cfxmagazine.com

Author: BioAge Labs, Inc.

BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025

March 24, 2026
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 19, 2026
BioAge Announces Pricing of Upsized $115.0 Million Public Offering

January 22, 2026
BioAge Announces Proposed Public Offering

January 20, 2026
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026

January 20, 2026